Today is: April 13, 2011

Evaluate Your Case Today

Calcagno & Associates

900 South Avenue, 3rd Floor
Staten Island, NY, 10314
Phone: 1-800-WE-FIGHT
             (718) 568-3585

By appointment only

Battery Place
New York, NY, 10004
Phone: (800) 933-4448

Grand Concourse Bronx, NY, 10451 Phone: (718) 933-4448

Bay Parkway Brooklyn, NY, 11214 Phone: (800) 487-6837

Name (First & Last)
DOB (Victims Date of Birth)


Email Address





Message about your case


The growing concern with the large pharmaceutical companies is because of the influence exercised over safety regulations in pursuit of financial gain instead of patient safety. The worlds second biggest maker of medical products, Johnson & Johnsons, manufactures a schizophrenia drug Risperdal which has annual global sales of $2.1 billion. While a J&J spokesperson claimed an update to the Risperdal label is indeed being made, and we will be sending out letters to health care professionals soon, the company had already issued Risperdal warning letters to Canadian doctors and pharmacists six months before announcing Risperdal side effect risks in the U.S.

Clinical trials testing Risperdal in Alzheimer patients heightened concerns that the occurrence of serious Risperdal side effects is higher than previously thought. Among 764 Risperdal patients, 29 cases of stroke and stroke-related events were seen, in addition to four deaths. A Public Citizen consumer watchdog group pharmacist and research analyst thinks that the recent Risperdal studies should push U.S. regulators to examine more deeply if younger aged schizophrenia patients are also more prone to experiencing Risperdal stroke and other side effects of Risperdal.

Approved in the 1990s as a type of new atypical anti-psychotic drug and thought to initially have fewer unwanted side effects, Risperdal uses upon approval only included schizophrenia treatment. Risperdal is often prescribed to control behavioral disorders in elderly patients with dementia and Alzheimers disease, including delusions, aggression, and anxiety, but the recent Risperdal stroke announcement shows there is an increased risk in prescribing Risperdal to a wider range of patients.

Public Citizen consumer watchdog group pharmacist and research analyst Larry Sasich thinks, The Risperdal label clearly states that there is no evidence this drug is safe or effective in treating dementia, and it looks like doctors are hurting people by prescribing it for this condition. Risperdal labeling changes will be implemented according to J&J to more accurately warn of the increased risk of Risperdal stroke and other Risperdal side effects that can include blood clots, hemorrhages, and death.

For more information on Risperdal side effects please contact us to confer with a Risperdal lawyer.

Return to Defective Drugs Listing


Keywords | Articles | Locations | Coupons |